CureVac Swiss AG has withdrawn its application to Swissmedic for the authorisation of its vaccine candidate CVnCoV.
Vaccine candidate CVnCoV no longer in rolling review procedure
19.10.2021
In a press release dated 12 October 2021, Tübingen-based biopharma company CureVac said that it would no longer be developing its first-generation COVID-19 vaccine to market readiness, and would instead be focusing on a second-generation COVID-19 vaccine.
Thus on 18 October 2021 CureVac Swiss AG also withdrew the application for authorisation that it had submitted to Swissmedic, the Swiss Agency for Therapeutic Products, in April 2021.